These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27508174)

  • 1. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.
    Ofuji K; Saito K; Yoshikawa T; Nakatsura T
    J Hepatocell Carcinoma; 2014; 1():35-42. PubMed ID: 27508174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
    Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
    Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPC-3 in hepatocellular carcinoma: current perspectives.
    Wu Y; Liu H; Ding H
    J Hepatocell Carcinoma; 2016; 3():63-67. PubMed ID: 27878117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide vaccines for hepatocellular carcinoma.
    Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
    Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Cancer Immunotherapy Targeting Glypican-3.
    Shimizu Y; Suzuki T; Yoshikawa T; Endo I; Nakatsura T
    Front Oncol; 2019; 9():248. PubMed ID: 31024850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glypican-3 in regulating Wnt in hepatocellular carcinomas.
    Gao W; Ho M
    Cancer Rep; 2011; 1(1):14-19. PubMed ID: 22563565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
    Suzuki S; Shibata K; Kikkawa F; Nakatsura T
    Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
    Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
    Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer peptide vaccine targeted glypican-3 antigen].
    Nakatsura T
    Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
    Zheng X; Liu X; Lei Y; Wang G; Liu M
    Front Oncol; 2022; 12():824208. PubMed ID: 35251989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
    Tsuchiya N; Yoshikawa T; Fujinami N; Saito K; Mizuno S; Sawada Y; Endo I; Nakatsura T
    Oncoimmunology; 2017; 6(10):e1346764. PubMed ID: 29123959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.